EGFR and head and neck squamous cell carcinoma: Based on clinical relevance, the EGFR antibody cetuximab is the only monoclonal antibody (mab) to have been approved by the US Food and Drug Administration and the European Medical Agency, for use in combination with radiation in cases of locally advanced diseases and added to platinum-based chemotherapy in cases of recurrent-metastatic SCCHN [6, 7].